SunTrust Banks, Inc. reiterated their buy rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a report issued on Thursday morning.
SRPT has been the topic of a number of other research reports. Cowen and Company restated a buy rating on shares of Sarepta Therapeutics in a research note on Friday, April 28th. Robert W. Baird restated an outperform rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, April 23rd. Leerink Swann restated an outperform rating and issued a $52.00 target price (up previously from $47.00) on shares of Sarepta Therapeutics in a research note on Saturday, April 29th. Piper Jaffray Companies set a $43.00 target price on Sarepta Therapeutics and gave the stock a buy rating in a research note on Thursday, May 18th. Finally, Vetr downgraded Sarepta Therapeutics from a strong-buy rating to a buy rating and set a $37.67 target price on the stock. in a research note on Monday, April 24th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Sarepta Therapeutics has an average rating of Buy and a consensus price target of $60.90.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up 6.06% on Thursday, reaching $43.41. The company had a trading volume of 7,594,038 shares. The stock has a 50-day moving average price of $33.69 and a 200-day moving average price of $32.07. Sarepta Therapeutics has a 12 month low of $22.61 and a 12 month high of $63.73. The stock’s market cap is $2.39 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.19) EPS. Analysts predict that Sarepta Therapeutics will post ($0.78) earnings per share for the current fiscal year.
WARNING: This story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://stocknewstimes.com/2017/07/21/sarepta-therapeutics-inc-nasdaqsrpt-given-buy-rating-at-suntrust-banks-inc.html.
A number of large investors have recently modified their holdings of SRPT. Russell Investments Group Ltd. boosted its stake in shares of Sarepta Therapeutics by 63.9% in the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 14,919 shares during the last quarter. Sigma Planning Corp boosted its stake in shares of Sarepta Therapeutics by 7.8% in the first quarter. Sigma Planning Corp now owns 12,895 shares of the biotechnology company’s stock worth $382,000 after buying an additional 930 shares during the last quarter. Columbus Circle Investors boosted its stake in shares of Sarepta Therapeutics by 175.0% in the first quarter. Columbus Circle Investors now owns 34,027 shares of the biotechnology company’s stock worth $1,007,000 after buying an additional 21,652 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth about $388,000. Finally, Bank of Montreal Can boosted its position in Sarepta Therapeutics by 1.0% in the first quarter. Bank of Montreal Can now owns 98,775 shares of the biotechnology company’s stock valued at $2,924,000 after buying an additional 996 shares during the last quarter. 73.13% of the stock is currently owned by institutional investors and hedge funds.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
